S&P 500   4,594.63 (+0.59%)
DOW   36,245.50 (+0.82%)
QQQ   389.94 (+0.29%)
AAPL   191.24 (+0.68%)
MSFT   374.51 (-1.16%)
META   324.82 (-0.71%)
GOOGL   131.86 (-0.51%)
AMZN   147.03 (+0.64%)
TSLA   238.83 (-0.52%)
NVDA   467.65 (-0.01%)
NIO   7.16 (-1.51%)
BABA   73.98 (-1.20%)
AMD   121.39 (+0.19%)
T   16.77 (+1.21%)
F   10.58 (+3.02%)
MU   75.93 (-0.25%)
CGC   0.62 (+10.75%)
GE   122.50 (+0.57%)
DIS   92.55 (-0.15%)
AMC   6.87 (+3.16%)
PFE   28.91 (-5.12%)
PYPL   59.65 (+3.54%)
XOM   102.99 (+0.24%)
S&P 500   4,594.63 (+0.59%)
DOW   36,245.50 (+0.82%)
QQQ   389.94 (+0.29%)
AAPL   191.24 (+0.68%)
MSFT   374.51 (-1.16%)
META   324.82 (-0.71%)
GOOGL   131.86 (-0.51%)
AMZN   147.03 (+0.64%)
TSLA   238.83 (-0.52%)
NVDA   467.65 (-0.01%)
NIO   7.16 (-1.51%)
BABA   73.98 (-1.20%)
AMD   121.39 (+0.19%)
T   16.77 (+1.21%)
F   10.58 (+3.02%)
MU   75.93 (-0.25%)
CGC   0.62 (+10.75%)
GE   122.50 (+0.57%)
DIS   92.55 (-0.15%)
AMC   6.87 (+3.16%)
PFE   28.91 (-5.12%)
PYPL   59.65 (+3.54%)
XOM   102.99 (+0.24%)
S&P 500   4,594.63 (+0.59%)
DOW   36,245.50 (+0.82%)
QQQ   389.94 (+0.29%)
AAPL   191.24 (+0.68%)
MSFT   374.51 (-1.16%)
META   324.82 (-0.71%)
GOOGL   131.86 (-0.51%)
AMZN   147.03 (+0.64%)
TSLA   238.83 (-0.52%)
NVDA   467.65 (-0.01%)
NIO   7.16 (-1.51%)
BABA   73.98 (-1.20%)
AMD   121.39 (+0.19%)
T   16.77 (+1.21%)
F   10.58 (+3.02%)
MU   75.93 (-0.25%)
CGC   0.62 (+10.75%)
GE   122.50 (+0.57%)
DIS   92.55 (-0.15%)
AMC   6.87 (+3.16%)
PFE   28.91 (-5.12%)
PYPL   59.65 (+3.54%)
XOM   102.99 (+0.24%)
S&P 500   4,594.63 (+0.59%)
DOW   36,245.50 (+0.82%)
QQQ   389.94 (+0.29%)
AAPL   191.24 (+0.68%)
MSFT   374.51 (-1.16%)
META   324.82 (-0.71%)
GOOGL   131.86 (-0.51%)
AMZN   147.03 (+0.64%)
TSLA   238.83 (-0.52%)
NVDA   467.65 (-0.01%)
NIO   7.16 (-1.51%)
BABA   73.98 (-1.20%)
AMD   121.39 (+0.19%)
T   16.77 (+1.21%)
F   10.58 (+3.02%)
MU   75.93 (-0.25%)
CGC   0.62 (+10.75%)
GE   122.50 (+0.57%)
DIS   92.55 (-0.15%)
AMC   6.87 (+3.16%)
PFE   28.91 (-5.12%)
PYPL   59.65 (+3.54%)
XOM   102.99 (+0.24%)

Pieris Pharmaceuticals (PIRS) Earnings Date, Estimates & Call Transcripts

$0.21
0.00 (0.00%)
(As of 12/1/2023 ET)
Compare
Today's Range
$0.20
▼
$0.21
50-Day Range
$0.20
▼
$0.33
52-Week Range
$0.16
▼
$1.97
Volume
524,279 shs
Average Volume
1.41 million shs
Market Capitalization
$20.55 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability
Skip Charts & View Estimated and Actual Earnings Data
Earnings Per ShareRevenue

PIRS Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

PIRS Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

Pieris Pharmaceuticals Analyst EPS Estimates

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20232($0.19)($0.09)($0.14)
Q2 20232($0.19)($0.16)($0.18)
Q3 20232($0.20)($0.18)($0.19)
Q4 20232($0.17)($0.16)($0.17)
FY 20238($0.75)($0.59)($0.67)
Q1 20241($0.17)($0.17)($0.17)
Q2 20241($0.17)($0.17)($0.17)
Q3 20241($0.19)($0.19)($0.19)
Q4 20241($0.19)($0.19)($0.19)
FY 20244($0.72)($0.72)($0.72)

PIRS Earnings Date and Information

Pieris Pharmaceuticals has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, April 3rd, 2024 based off prior year's report dates.

Pieris Pharmaceuticals Earnings History by Quarter

Export to Excel
DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueCall Transcript
4/3/2024
Estimated)		------- 
8/10/2023Q2 2023($0.16)$0.05+$0.21$0.05$3.76 million$20.06 million
5/10/2023Q1 2023($0.14)($0.18)($0.04)($0.18)$6.51 million$1.94 million    
3/29/2023Q4 2022($0.13)($0.11)+$0.02($0.11)$6.51 million$5.85 million
11/2/2022Q3 2022($0.16)($0.13)+$0.03($0.13)$4.51 million$5.37 million    
8/4/2022Q2 2022($0.11)($0.14)($0.03)($0.14)$10.47 million$3.70 million
5/11/2022Q1 2022($0.12)($0.07)+$0.05($0.07)$11.31 million$10.99 million      
3/1/2022Q4 2021($0.30)($0.13)+$0.17($0.13)$4.91 million$8.44 million
11/2/2021Q3 2021($0.24)($0.24)-($0.24)$7.98 million$4.06 million  
8/4/2021Q2 2021($0.20)($0.25)($0.05)($0.25)$8.53 million$3.29 million  
5/17/2021Q1 2021($0.17)($0.07)+$0.10($0.07)$6.47 million$15.63 million  
3/29/2021Q4 2020($0.24)($0.26)($0.02)($0.26)$3.82 million$1.88 million    












Pieris Pharmaceuticals Earnings - Frequently Asked Questions

When is Pieris Pharmaceuticals's earnings date?

Pieris Pharmaceuticals has not confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, April 3rd, 2024 based off last year's report dates. Learn more on PIRS's earnings history.

How much revenue does Pieris Pharmaceuticals generate each year?

Pieris Pharmaceuticals (NASDAQ:PIRS) has a recorded annual revenue of $25.90 million.

How much profit does Pieris Pharmaceuticals generate each year?

Pieris Pharmaceuticals (NASDAQ:PIRS) has a recorded net income of -$33.28 million. PIRS has generated -$0.35 earnings per share over the last four quarters.

What is Pieris Pharmaceuticals's EPS forecast for next year?

Pieris Pharmaceuticals's earnings are expected to grow from ($0.35) per share to ($0.20) per share in the next year.


More Earnings Resources from MarketBeat

Related Companies:
Earnings Tools:
Earnings By Country:
Latest Articles:
This page (NASDAQ:PIRS) was last updated on 12/1/2023 by MarketBeat.com Staff

My Account -